Treatment of psoriasis and psoriatic arthritis in patients with concomitant chronic, severe viral infections, particularly HIV or HBV, represents a challenge, due to contraindication to conventional immunomodulating systemic drugs and biologics, including anti-TNF alpha, anti-IL12/23, and anti-IL17 agents. Recently, apremilast, a selective inhibitor of phosphodiesterase E4 has been suggested to be a safe and effective therapeutic option in HIV-infected population with psoriatic arthritis. We report the case of a patient with psoriatic arthritis and concomitant HIV and HBV infection successfully treated with apremilast.

Manfreda, V., Esposito, M., Campione, E., Bianchi, L., Giunta, A. (2019). Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections. POSTGRADUATE MEDICINE, 131(3), 239-240 [10.1080/00325481.2019.1575613].

Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections

Campione E.;Bianchi L.;Giunta A.
2019-01-01

Abstract

Treatment of psoriasis and psoriatic arthritis in patients with concomitant chronic, severe viral infections, particularly HIV or HBV, represents a challenge, due to contraindication to conventional immunomodulating systemic drugs and biologics, including anti-TNF alpha, anti-IL12/23, and anti-IL17 agents. Recently, apremilast, a selective inhibitor of phosphodiesterase E4 has been suggested to be a safe and effective therapeutic option in HIV-infected population with psoriatic arthritis. We report the case of a patient with psoriatic arthritis and concomitant HIV and HBV infection successfully treated with apremilast.
2019
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35 - MALATTIE CUTANEE E VENEREE
English
Apremilast; HIV; psoriasis; psoriatic arthritis; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; HIV Infections; Hepatitis B; Humans; Male; Thalidomide; Treatment Outcome
Manfreda, V., Esposito, M., Campione, E., Bianchi, L., Giunta, A. (2019). Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections. POSTGRADUATE MEDICINE, 131(3), 239-240 [10.1080/00325481.2019.1575613].
Manfreda, V; Esposito, M; Campione, E; Bianchi, L; Giunta, A
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Apremilast efficacy and safety in a psoriatic.pdf

solo utenti autorizzati

Licenza: Copyright dell'editore
Dimensione 2.63 MB
Formato Adobe PDF
2.63 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/217230
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact